Improving detection of drug-resistant infections caused by Acinetobacter baumannii.
Official title: Evolving the standard of care for carbapenem resistant infections, through the development of a phenotypic assay capable of DETECTing and classifying carbapenemases
Funded at Bioamp Diagnostics, INC. · NIH-11064781 · Data updated 2026-11-12
This study is working on a new test that can quickly find and identify tough-to-treat bacteria called Acinetobacter baumannii, which can resist many antibiotics, so doctors can make faster and better treatment decisions for patients with these infections.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bioamp Diagnostics, INC. NIH-funded |
| Lab location | 1 site (San Mateo, UNITED STATES) |
| Project start | April 2, 2024 |
| Project end | June 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $79,309 |
| NIH project number | 5R43AI181482-02 |
| Project ID | NIH-11064781 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with infections caused by carbapenem-resistant Acinetobacter baumannii.
✕Less likely to help
Patients with infections caused by non-carbapenem-resistant bacteria may not benefit from this research.
What this research studies
This research focuses on developing a new biochemical assay that can quickly detect and classify carbapenem-resistant organisms, specifically targeting Acinetobacter baumannii. By integrating this assay into standard antibiotic susceptibility testing, the goal is to provide faster results, potentially reducing the time to identify these dangerous infections from several days to just hours. This rapid detection could significantly improve treatment decisions and infection control measures, ultimately enhancing patient outcomes. The approach aims to address the urgent public health threat posed by these resistant bacteria.
Why it matters
Potential benefit: If successful, this research could lead to faster and more effective treatment options for patients with carbapenem-resistant infections.
How similar studies have gone: Previous research has shown promise in developing rapid diagnostic tests for antibiotic resistance, indicating that this approach has potential for success.
Where this research is happening
-
Bioamp Diagnostics, INC.
San Mateo, United States Active
Researchers
- Principal investigator: Jackson, Nicole — Bioamp Diagnostics, INC.
- Study coordinator: Jackson, Nicole
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.